VEGFA and cancer: Third, neither Taiwan Cancer Registry nor the National Health Insurance Research Database can identify cancer progression, which limits us from evaluating the efficacy of anti-VEGF treatment on survival probability in patients initially diagnosed with stage III colorectal cancer.